<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02580773</url>
  </required_header>
  <id_info>
    <org_study_id>AOR14068</org_study_id>
    <nct_id>NCT02580773</nct_id>
  </id_info>
  <brief_title>Therapeutic Anticoagulation Strategy for Acute Chest Syndrome</brief_title>
  <acronym>TASC</acronym>
  <official_title>A Prospective, Randomized, Double-blind, Placebo Controlled, Multi-national Study of Therapeutic Anticoagulation Strategy for Acute Chest Syndrome in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute Chest Syndrome (ACS) is a pulmonary complication of sickle cell disease (SCD)
      representing the leading cause of death and the second cause of hospitalization among adult
      patients. Pulmonary vaso-occlusion is one of the main pathophysiologic hypotheses during ACS.
      Our hypothesis is that therapeutic anticoagulation may reduce the severity of ACS via the
      alleviation of pulmonary thrombosis. The main objective of this prospective, randomized,
      double-blind study is to test the efficacy and safety of a curative anticoagulation strategy
      during ACS. The main efficacy endpoint is time to ACS resolution. The main safety endpoint is
      number of major bleedings.

      A thoracic CT scan will be performed to check for pulmonary artery thrombosis. If the CT scan
      is positive (thrombosis within a large elastic artery), the patient will not be randomized
      and will be treated with a curative anticoagulation. If the CT scan is negative, the patient
      will be randomized to receive subcutaneous anticoagulation with low molecular weight heparin
      (tinzaparin) either at a curative dose (175 Unit International (UI)/kg/day for 7 days) or at
      a prophylactic dose (4500 UI/day).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 16, 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The main efficacy endpoint is time to ACS resolution</measure>
    <time_frame>up to 15 days</time_frame>
    <description>The delay between randomization and ACS resolution</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of major bleedings</measure>
    <time_frame>up to 15 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of complicated ACS</measure>
    <time_frame>up to 15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood volume exchanged</measure>
    <time_frame>up to 15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative dose of opioids</measure>
    <time_frame>up to 15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>up to 15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay</measure>
    <time_frame>up to 15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of non-major bleedings</measure>
    <time_frame>up to 15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of readmissions and thromboembolic events within 6 months</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Anemia</condition>
  <condition>Sickle Cell</condition>
  <condition>Acute Chest Syndrome</condition>
  <condition>Low-Molecular-Weight Heparin</condition>
  <arm_group>
    <arm_group_label>Prophylactic anticoagulation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Curative anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prophylactic anticoagulation ( INNOHEP®)</intervention_name>
    <description>subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a prophylactic dose (4500 UI/day)</description>
    <arm_group_label>Prophylactic anticoagulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Curative anticoagulation ( INNOHEP®)</intervention_name>
    <description>subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a curative dose (175 UI/kg/day for 7 days)</description>
    <arm_group_label>Curative anticoagulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Major sickle cell syndrome (SS, SC, Sβ)

          -  ACS defined by the association of a new infiltrate on chest X-ray or CT scan and a
             respiratory symptom or abnormal chest auscultation

          -  Written, informed consent

        Main Exclusion Criteria:

          -  Pregnancy, post-partum

          -  Iodine allergy

          -  Extreme weight (&lt;40 kg or &gt; 100 kg)

          -  Moderate to severe renal insufficiency

          -  Moya-moya disease

          -  Symptomatic cerebral aneurysm

          -  Major transfusional risk

          -  Uncontrolled severe retinopathy

          -  All other contra-indications to curative anti-coagulation by tinzaparin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard Maitre, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Armand Mekontso Dessap, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Armand Mekontso Dessap, MD, PhD</last_name>
    <phone>(0)149812394</phone>
    <phone_ext>+33</phone_ext>
    <email>armand.dessap@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henri Mondor Hospital</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armand Mekontso Dessap, MD, PhD</last_name>
      <phone>(0)149812394</phone>
      <phone_ext>+33</phone_ext>
      <email>armand.dessap@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Bernard Maitre, MD, PhD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Qari MH, Aljaouni SK, Alardawi MS, Fatani H, Alsayes FM, Zografos P, Alsaigh M, Alalfi A, Alamin M, Gadi A, Mousa SA. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thromb Haemost. 2007 Aug;98(2):392-6.</citation>
    <PMID>17721622</PMID>
  </reference>
  <reference>
    <citation>Mekontso Dessap A, Deux JF, Abidi N, Lavenu-Bombled C, Melica G, Renaud B, Godeau B, Adnot S, Brochard L, Brun-Buisson C, Galacteros F, Rahmouni A, Habibi A, Maitre B. Pulmonary artery thrombosis during acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med. 2011 Nov 1;184(9):1022-9. doi: 10.1164/rccm.201105-0783OC.</citation>
    <PMID>21836136</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2015</study_first_submitted>
  <study_first_submitted_qc>October 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2015</study_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sickle cell disease</keyword>
  <keyword>Anemia</keyword>
  <keyword>Rare disease</keyword>
  <keyword>Reanimation</keyword>
  <keyword>Prophylactic anticoagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Chest Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

